Table 2 Selected subgroup analysis of survival in the intent-to-treat population.

Histotype

HNC

0.77 (0.65, 0.91)

0.003

0.93 (0.80, 1.08)

0.357

GC/GEJC

0.83 (0.48, 1.44)

0.509

1.02 (0.36, 2.87)

0.973

UC

0.77 (0.68, 0.87)

≤0.001

0.97 (0.85, 1.11)

0.660

NSCLC

0.72 (0.66, 0.80)

≤0.001

0.75 (0.65, 0.87)

≤0.001

MM

1.75 (1.10, 2.78)

0.018

1.44 (1.05, 1.97)

0.026

Mm

0.69 (0.50, 0.96)

0.029

0.60 (0.43, 0.83)

0.002

RCC

0.74 (0.59, 0.93)

0.010

0.78 (0.69, 0.88)

≤0.001

CRC

1.08 (0.85, 1.37)

0.533

1.31 (1.05, 1.62)

0.014

Regimen

Combination therapy

0.78 (0.66, 0.91)

0.002

0.75 (0.65, 0.86)

≤0.001

Monotherapy

0.76 (0.70, 0.82)

≤0.001

0.84 (0.74, 0.95)

0.007

Combination Drug

Chemotherapy

0.68 (0.57, 0.81)

≤0.001

0.64 (0.55, 0.76)

≤0.001

Targeted therapy

0.94 (0.71, 1.26)

0.694

0.94 (0.74, 1.19)

0.602

Treatment in control group

Chemotherapy

0.74 (0.68, 0.80)

≤0.001

0.79 (0.69, 0.90)

≤0.001

Placebo

0.64 (0.53, 0.77)

≤0.001

0.55 (0.47, 0.65)

≤0.001

Biologics

0.93 (0.74, 1.16)

0.496

0.97 (0.80, 1.17)

0.730

Age

<65yr

0.77 (0.69, 0.87)

≤0.001

0.82 (0.67, 1.02)

0.078

≥65yr

0.76 (0.67, 0.84)

≤0.001

0.84 (0.69, 1.01)

0.067

≥65 to <75yr

0.64 (0.54, 0.77)

≤0.001

0.71 (0.39, 1.29)

0.264

≥75yr

0.88 (0.53, 1.46)

0.616

0.98 (0.52, 1.85)

0.956

Sex

Male

0.74 (0.69, 0.79)

≤0.001

0.75 (0.63, 0.90)

0.002

Female

0.75 (0.63, 0.88)

≤0.001

0.82 (0.61, 1.11)

0.196

ECOG

0

0.81 (0.71, 0.93)

0.002

0.91 (0.67, 1.22)

0.530

1

0.74 (0.68, 0.80)

≤0.001

0.77 (0.64, 0.93)

0.005

Smoking

Current/Former

0.75 (0.68, 0.83)

≤0.001

0.72 (0.57, 0.89)

0.003

Never

0.81 (0.66, 1.00)

0.045

1.00 (0.55, 1.79)

0.991

Line

First-line

0.72 (0.62, 0.84)

≤0.001

0.70 (0.60, 0.81)

≤0.001

Subsequent line

0.78 (0.73, 0.85)

≤0.001

0.89 (0.79, 1.01)

0.081

Masking

Double-blind

0.64 (0.56, 0.74)

≤0.001

0.57 (0.49, 0.67)

≤0.001

Open-label

0.81 (0.75, 0.87)

≤0.001

0.91 (0.82, 1.00)

0.054

Target spot

PD-L1

0.86 (0.80, 0.92)

≤0.001

0.88 (0.75, 1.04)

0.143

PD-1

0.71 (0.64, 0.78)

≤0.001

0.77 (0.68, 0.87)

≤0.001

Anti-PD-1/PD- L1 inhibitor used

Atezolizumab

0.84 (0.78, 0.91)

≤0.001

0.86 (0.74, 1.00)

0.045

Pembrolizumab

0.70 (0.63, 0.79)

≤0.001

0.76 (0.65, 0.89)

≤0.001

Nivolumab

0.71 (0.59, 0.86)

≤0.001

0.78 (0.63, 0.98)

0.029

Avelumab

0.94 (0.79, 1.12)

0.484

1.11 (0.68, 1.83)

0.675

CNS Metastasis

Yes

0.78 (0.48, 1.25)

0.303

0.64 (0.42, 0.97)

0.036

No

0.70 (0.61, 0.80)

≤0.001

0.66 (0.52, 0.83)

≤0.001

Liver Metastasis

Yes

0.81 (0.68, 0.96)

0.017

—

—

No

0.71 (0.62, 0.82)

≤0.001

—

—

RAS

Mutant

0.87 (0.63, 1.21)

0.408

1.09 (0.82, 1.43)

0.563

Wildtype

0.99 (0.81, 1.20)

0.900

1.45 (1.14, 1.84)

0.002

EGFR

Mutant

1.11 (0.80, 1.52)

0.538

1.57 (1.07, 2.31)

0.022

Wildtype

0.70 (0.63, 0.77)

≤0.001

0.83 (0.73, 0.95)

0.007